谭冠昶,卢志南,梁逸伦,张海彤,宋光远,林逸贤,李沛威

• 1:澳门镜湖医院心内科
• 2:首都医科大学附属北京安贞医院心脏瓣膜病介入中心
• 3:澳门科大医院心内科
• 4:中山大学附属第三医院心内科

摘要(Abstract)：

目的旨在评估经皮MitraClip介入治疗外科手术高风险或有手术禁忌的严重二尖瓣反流(MR)患者中期的安全性和有效性。方法本研究为单中心、回顾性队列研究,纳入2016年1月1日至2019年12月31日于中国澳门镜湖医院接受经皮MitraClip介入治疗的重度MR患者。收集患者住院期间的临床基线特征和超声心动图指标,术后6个月以及1年进行随访,评估患者心功能状态、超声心动图指标变化以及严重不良并发症发生情况。结果共入选25例患者,平均年龄(74.5±6.2)岁,其中男8例(8/25);退行性MR 9例(9/25),功能性MR 16例(16/25)。25例患者术后即刻MR面积和肺动脉收缩压(PASP)较术前显著下降[分别是(4.58±2.52)cm~2比(11.51±5.31)cm~2,P<0.001;(38.00±10.09)mmHg比(46.48±14.67)mmHg(1 mmHg=0.133 kPa),P=0.026];三尖瓣反流(TR)面积、左心室舒张末期内径、左心室收缩末期内径及左心室射血分数等均较术前有所改善,但差异均无统计学意义(均P>0.05)。术后6个月及1年时,MR面积、TR面积及PASP均较术前显著改善(均P<0.05)。在围术期及随访过程中无严重并发症和死亡发生。结论经皮MitraClip介入治疗对外科手术高风险或有手术禁忌的严重MR具有较好的安全性和有效性,且中期随访时MR显著改善。

关键词(KeyWords)： 二尖瓣反流;外科手术;高风险;经皮二尖瓣修复

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 谭冠昶,卢志南,梁逸伦,张海彤,宋光远,林逸贤,李沛威

参考文献(References)：

• [1] Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community:the emerging role of mitral regurgitation. Circulation, 2005, 111(3):295-301.
• [2] Jones EC, Devereux RB, Roman MJ, et al. Prevalence and correlates of mitral regurgitation in a population-based sample(the Strong Heart Study). Am J Cardiol, 2001, 87(3):298-304.
• [3] Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases:a population-based study. Lancet, 2006, 368(9540):1005-1011.
• [4]聂静雨，王增武，张林峰，等. 35岁及以上人群二尖瓣反流现状及其影响因素研究.中国循环杂志，2017,32(5):475-479.
• [5]齐喜玲，许海燕，刘庆荣，等.中国老年退行性心脏瓣膜病住院患者诊疗现状分析.中国循环杂志，2019,34(8):771-776.
• [6] Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J,2007,28(11):1358-1365.
• [7] Taramasso M, Candreva A, Pozzoli A, et al. Current challenges in interventional mitral valve treatment. J Thorac Dis,2015,7(9):1536-1542.
• [8] Andalib A, Mamane S, Schiller I, et al. A systematic review and meta-analysis of surgical outcomes following mitral valve surgery in octogenarians:implications for transcatheter mitral valve interventions. EuroIntervention,2014, 9(10):1225-1234.
• [9]诸葛瑞琪，张明子，侯晓沛，等.老年二尖瓣反流住院患者治疗方案选择的相关因素分析.中华老年医学杂志，2018,37(5):496-500.
• [10] Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients:results of the EVERESTⅡstudy. J Am Coll Cardiol, 2014, 64(2):172-181.
• [11] Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitralvalve repair in patients with heart failure. N Engl J Med, 2018, 379(24):2307-2318.
• [12] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4):e25-e197.
• [13] Boekstegers P, Hausleiter J, Baldus S, et al. Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol, 2014, 103(2):85-96.
• [14] Grigioni F, Russo A, Pasquale F, et al. Clinical use of doppler echocardiography in organic mitral regurgitation:from diagnosis to patients’ management. J Cardiovasc Ultrasound, 2015, 23(3):121-133.
• [15] Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique:six-month results of the EVEREST PhaseⅠClinical Trial. J Am Coll Cardiol,2005, 46(11):2134-2140.
• [16] Mauri L, Garg P, Massaro JM, et al. The EVERESTⅡTrial:design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation.Am Heart J, 2010, 160(1):23-29.
• [17] Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med, 2011, 364(15):1395-1406.
• [18] Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation:5-year results of EVERESTⅡ. J Am Coll Cardiol, 2015, 66(25):2844-2854.
• [19] Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice:initial results from the German transcatheter mitral valve interventions(TRAMI)registry. Eur J Heart Fail,2012, 14(9):1050-1055.
• [20] Carroll JD, Edwards FH, Marinac-Dabic D, et al. The STS-ACC transcatheter valve therapy national registry:a new partnership and inf rastructure f or the introduction and surveillance of medical devices and therapies. J Am Coll Cardiol, 2013, 62(11):1026-1034.
• [21] Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-to-edge repair:in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol, 2014, 64(9):875-884.
• [22] Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world:early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized postapproval study of the MitraClip therapy in Europe. J Am Coll Cardiol, 2013, 62(12):1052-1061.
• [23] Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol, 2014, 63(22):e57-e185.
• [24] Al-Bawardy R, Vemulapalli S, Thourani VH, et al. Association of Pulmonary Hypertension with clinical outcomes of transcatheter mitral valve repair. JAMA Cardiol, 2020, 5(1):47-56.
• [25] Ben-Yehuda O, Shahim B, Chen S, et al. Pulmonary hypertension in transcatheter mitral valve repair f or secondary mitral regurgitation:the COAPT trial. J Am Coll Cardiol, 2020, 76(22):2595-2606.